Varian Will Acquire Embolic Bead Asset From Boston Scientific

Comments
Loading...

Varian Medical Systems VAR will acquire Boston Scientific’s BSX portfolio of drug-loadable microsphere and bland embolic bead products. Terms of the transaction were not disclosed.

Boston Scientific’s portfolio of products treat arteriovenous malformations, which is a tangle of abnormal and poorly formed blood vessels and hypervascular tumors. Varian will not acquire any of the Boston Scientific operations, but plans to manufacture and distribute the products.

"This acquisition from Boston Scientific will strengthen Varian's growing position in the high-value interventional oncology segment and is consistent with our long-term strategy to become a global leader in multidisciplinary, integrated cancer solutions," said Dow Wilson, CEO of Varian.

Varian shares were trading down 0.30% at $139.20 Tuesday afternoon.

Related Links:

Karuna Therapeutics Opens Above IPO Price

ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development

Overview Rating:
Speculative
50%
Technicals Analysis
100
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!